Response to Bacillus Calmette-Guérin Vaccine in Full-Term and Preterm Infants

ABSTRACT

The purpose of this study was to compare the delayed response to Bacillus Calmette-Guérin (BCG) immunization in preterm infants 31.4 to 34.6 weeks of age with full-terms infants by tuberculin test (tuberculin skin test with purified protein derivative [PPD]). One hundred newborns were studied from November 2000 to April 2002, consecutively allocated by convenience in two groups. Group I (GI) included 50 preterm infants from 30 to 34.2 weeks of age at inclusion and 31.4 to 34.6 weeks of age at vaccination. Group II (GII) included 50 full-term newborns. Sick or malnourished patients and those with severe malformations were not included. Newborns were evaluated at 4, 8, and 12 weeks after BCG application for scar measurement. Sixteen weeks after BCG, the PPD with Tubersol was performed. It was defined as a positive reaction when the scar diameter was of 5 mm or more; the same criterion was used for PPD response. Forty-two patients from each group concluded the study. The percentage of positive scar (GI, 64%; GII, 80%; p = 0.142) and the mean of scar diameter (4.5 and 5 mm, respectively) were not statistically significantly different. The rate of positive PPD in GI (81%) and GII (86%), and the mean of PPD in GI (6.7 mm) and GII (6.8 mm) were not statistically different (p = 0.74). Complications were not observed. This trial showed similar response to PPD after BCG vaccination in preterm and full-term infants.

KEYWORDS

BCG - preterm infants - purified protein derivative (PPD) response

REFERENCES

• 1 Enserink M. Driving a stake into resurgent Tb. In: Vaccines and immunity news.  Science. 2001;  293 234-235
• 2 Raviglione M C, Snider D E, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.  JAMA. 1995;  273 220-226
• 3 World Health Organization .BCG Vaccine. Immunization, Vaccines and Biologicals. Available at: http://www.who.int/vaccines/en/tuberculosis2.shtml Accessed April 22, 2004
• 4 Instituto Nacional de Estastica Geografía e Informatica .Dirección General de Información y Evaluación del Desempeño. Mexico DF; Instituto Nacional de Estadistica Geografía e Informatica 2003
• 5 World Health Organization .Global Tuberculosis Control. The Americas. WHO Report. Geneva, Switzerland; World Health Organization 2004
• 6 Cohn D L. Use of the Bacillus Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine.  Am J Med Sci. 1997;  313 372-376
• 7 Young D B, Robertson B D. TB vaccines: global solutions for global problems.  Science. 1999;  284 1479-1480
• 8 Horwitz M A. New recombinant BCG vaccines provide greater immunity for tuberculosis.  Proc Natl Acad Sci USA. 2000;  97 13853-13858
• 9 Doherty T M. Oral subunit vaccine and adjuvant protects against experimental TB infection.  Infect Immun. 2002;  70 3111-3121
• 10 Ramos B R, Villalobos V H, Macías Parra M. Vacuna contra la tuberculosis. In: Macías-Parra M Temas de Pediatría: Inmunizaciones. Asoc Mex de Pediatría A. C. México. Mexico DF; Editorial Interamericana, McGraw-Hill 1995: 39-52
• 11 Chatwal J, Verma M, Thaper N, Aneja R. Waning of post-vaccinal allergy afterneonatal BCG vaccination.  Indian Pediatr. 1994;  31 1529-1533
• 12 López-Antuñano F J. Usos y efectos del bacilo de Mycobacterium bovis Calmette Guerin (Vacunación con BCG).  Salud Publica Mex. 1997;  39 156-161
• 13 Sirinavin S, Chotpitayasunondh T, Suwanjutha S, Sunalom P, Chantarojanasiri T. Protective efficacy of neonatal bacillus Calmette-Guérin vaccination against tuberculosis.  Pediatr Infect Dis J. 1991;  10 359-365
• 14 Ormerod L P, Garnett J M. Tuberculin skin reactivity four years after neonatal BCG vaccination.  Arch Dis Child. 1992;  67 530-531
• 15 Kelly P, McKeown D, Clancy L. Neonatal BCG vaccination in Ireland: evidence of its efficacy in the prevention of childhood tuberculosis.  Eur Respir J. 1997;  10 619-623
• 16 Houston S, Fanning A, Soskolne C L, Fraser N. The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis.  Am J Epidemiol. 1990;  31 340-348
• 17 Colditz G A, Berkey C S, Mosteller F et al.. The efficacy of bacillus Calmette- Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.  Pediatrics. 1995;  96 29-35
• 18 Brewer T F. Preventing Tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analyses of the literature.  Clin Infect Dis. 2000;  31(Suppl 3) S64-S67
• 19 Smith S, Jacobs R F, Wilson C B. Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity.  J Pediatr. 1997;  131 16-26
• 20 Dannenberg Jr A M. Fisiopatología aspectos básicos. In: Schlossberg D Tuberculosis e Infecciones por Micobacterias no Tuberculosas. 4th ed. México DF; McGraw-Hill Interamericana 2000: 19-54
• 21 Chadha V K. Tuberculin test.  Indian J Pediatr. 2001;  68 53-58
• 22 Commitee on Infectious Diseases. Screening for tuberculosis in infants and children.  Pediatrics. 1994;  93 131-134
• 23 Steele R W. A new look at TB skin testing in children. Presented at the American Academy of Pediatrics, Annual Meeting October 9-13, 1991 Washington, DC;
• 24 Al-Kassimi F A, Al-Hajjaj M S, Al-Oraney I O, Bamgboye E A. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?.  Am J Respir Crit Care Med. 1995;  152 1575-1578
• 25 Uyan A P, Baskin E, Büyükbese E, Gökalp A S. Evaluating Bacillus Calmette-Guérin vaccination by tuberculin skin test response.  Indian Pediatr. 2000;  37 1106-1110
• 26 Jacob T J. Immunization dialogue. BCG vaccination: some practical dilemmas.  Indian Pediatr. 1999;  36 941-944
• 27 Jacob T J. BCG vaccination.  Indian Pediatr. 2000;  37 332-333
• 28 Santiago E M, Lawson E, Gillenwater K et al.. A prospective study of Bacillus Calmette-Guérin scar formation and tuberculin skin test reactivity in infants in Lima, Peru.  Pediatrics. 2003;  112 e298-e302
• 29 Kröger L, Katila M L, Korppi M, Brander E, Pietikäinen M. Rapid decrease in tuberculin skin test reactivity at preschool age after newborn vaccination.  Acta Paediatr. 1992;  81 678-681
• 30 Grindulis H, Baynham M ID, Scott P H, Thompson R A, Wharton B A. Tuberculin response two years after BCG vaccination at birth.  Arch Dis Child. 1984;  59 614-619
• 31 Sepúlveda R L, Ferrer X, Latrach C, Sorensen R U. The influence of Calmette-Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults.  Am Rev Respir Dis. 1990;  142 24-28
• 32 Fine P E. Variation in protection by BCG: implications of and for heterologous immunity.  Lancet. 1995;  346 1339-1345
• 33 Agarwal A, Dutta A K. Timing and dose of BCG vaccination in infants as assessed by post-vaccination tuberculin sensitivity.  Indian Pediatr. 1995;  32 635-639
• 34 Dawodu A H. Tuberculin conversion following BCG vaccination in preterm infants.  Acta Paediatr Scand. 1985;  74 564-567
• 35 Sedaghatian M R, Kardouni K. Tuberculin response in preterm infants after BCG vaccination at birth.  Arch Dis Child. 1993;  69 309-311
• 36 Sedaghatian M R, Hashem F, Moshaddeque Hossain M. Bacille Calmette-Guérin vaccination in pre-term infants.  Int J Tuberc Lung Dis. 1998;  2 679-682
• 37 Thayyil-Sudhan S, Singh M, Paul V K, Deorari A K, Kumar A. Safety and effectiveness of BCG vaccination in preterm babies.  Arch Dis Child. 1999;  81 64F-66F
• 38 Norma Oficial Mexicana NOM-031-SSA2 .1999 Para la atención a la salud del niño. Mexico DF; Secretaría de Salud, Diario Oficial de la Federación Mexico June 9, 2000
• 39 Benavides-Vázquez L. Inmunizaciones. In: Macías-Parra M Temas de Pediatría Inmunizaciones. Asoc Mex de Pediatría A. C. México; Ed Interamericana McGraw-Hill 1995: 1-4
• 40 Conway S P. Opportunistic immunization in hospital.  Arch Dis Child. 1999;  81 422-425
• 41 Capurro H, Konichezky S A, Fonseca D, Caldeyro-Barcia R. A simplified method for diagnosis of gestational age in the newborn infant.  J Pediatr. 78;  93 120
• 42 Lubchenco L O, Hansman C, Boyd E. Intrauterine growth in length and head circunference as estimated from live births at gestational age from 26 to 42 weeks.  Pediatrics. 1966;  37 403-408
• 43 Bouros D, Seros G, Panaretos C H, Charalambos V, Siafakas N. Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux Test).  Chest. 1991;  99 416-419
• 44 Glantz S A. Primer of Biostatistics. 4th ed. New York; McGraw-Hill Medical 1996
• 45 Dawson-Saunders B, Trapp R G. Bioestadíca Médica. 2nd ed. Mexico; Edit El Manual Moderno 1997
• 46 Martínez-González M T, Vázquez C JL, Gallardo M G. Effectiveness of the BCG vaccine to prevent severe extra pulmonary Tb in children.  Int Pediatr. 2002;  17 110-114
• 47 Menzies R, Visandjee B. Effect of bacilli Calmette-Guérin vaccination on tuberculin reactivity.  Am Rev Respir Dis. 1992;  145 621-625
• 48 U.S. Preventive Services Task Force Committee .Screening for tuberculosis infection-including Bacillus Calmette-Guérin immunization. In: Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD; Williams & Wilkins 1996: 277-286
• 49 Rani H S, Vijayalakshmi V, Kumar S, Kiran A L, Suman L G, Murthy K JR. Cell mediated immunity in children with scar failure following BCG vaccination.  Indian Pediatr. 1998;  35 123-127
• 50 Valenzuela N T, Ferrer X, Leal I, Pacheco M, Castillo N, Cumsille F. Comparative study of the efficacy of two types of BCG vaccines administered in different doses.  Rev Med Chil. 1998;  126 1126-1131
• 51 Marchant A, Goetghebuer T, Ota M O et al.. Newborns develop a Th1-Type immune response to Mycobacterium bovis Bacillus Calmette-Guérin Vaccination.  J Immunol. 1999;  163 2249-2255
• 52 Jiao X, Lo-Man R, Guermonprez P et al.. Dendritic cells are host cells for Mycobacteria in vivo that trigger innate and acquired immunity.  J Immunol. 2002;  168 1294-1301
• 53 Ota M O, Vekemans J, Schlegel-Hauter S E et al.. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination.  J Immunol. 2002;  168 919-925
• 54 Hussey G D, Watkins M L, Goddard E et al.. Neonatal mycobacterial specific cytotoxic T-lymphocyte an cytokine profiles in response to distinct BCG vaccination strategies.  Immunology. 2002;  105 314-324
• 55 Siegrist C A. Neonatal and early life vaccinology. Review.  Vaccine. 2001;  19 3931-3946
• 56 Kovarik J, Siegrist C A. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators (Special feature: Immunological adjuvants).  Immunol Cell Biol. 1998;  76 222-236
• 57 Kröger L, Brander E, Korppi M et al.. Osteitis after newborn vaccination with three different Bacillus Calmette-Guérin vaccines: twenty-nine years of experience.  Pediatr Infect Dis. 1994;  12 113-116
• 58 Peter G, Hall C B, Halsey N A, Marcy S M, Pickering L K, Orenstein N A. Tuberculosis. In: Red Book. Enfermedades Infecciosas en Pediatría. 24th ed. Buenos Aires, Argentina; Edit Panamericana 1999: 565-589